Loading
A computer method that reads chemical marks on DNA in the blood to measure how much breast cancer is there and whether it still carries the oestrogen receptor.
METER (Paoli et al., Genome Medicine 2026) uses tumour-type-specific DNA methylation patterns in low-pass (0.5 to 1x) whole-methylome sequencing of plasma to detect, quantify and subtype ctDNA without tumour tissue. In longitudinal samples from metastatic breast cancer it was more strongly associated with outcome than other ctDNA methods and matched circulating tumour cell counts, including below 3 per cent tumour content. In the full text, oestrogen receptor calls on samples with at least 5 per cent tumour content had an accuracy of 0.93 when the two cohorts were combined (80 ER-positive against 12 ER-negative samples). The authors state that subtype accuracy depends on tumour content.
Plasma methylation is deconvolved into reference components, including oestrogen receptor positive and negative breast cancer, and the predominant component assigns the subtype.
Query for this technology: (TITLE:"METER" OR ABSTRACT:"METER" OR TITLE:"methylome-based ctDNA detection and subtyping" OR ABSTRACT:"methylome-based ctDNA detection and subtyping") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about METER (methylome-based ctDNA detection and subtyping), not a curated reading list.
Shares Griffin (nucleosome profiling of cell-free DNA), Read methylation and mutation on the same cell-free DNA fragment to tell what kind of cancer is left, Cell-free DNA (cfDNA), Estrogen receptor (ERα).
Shares Griffin (nucleosome profiling of cell-free DNA), Naming which clone or phenotype is left after treatment, Cell-free DNA (cfDNA), DNA methylation profiling.
Shares Naming which clone or phenotype is left after treatment, Cell-free DNA (cfDNA), Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Griffin (nucleosome profiling of cell-free DNA), Naming which clone or phenotype is left after treatment, Cell-free DNA (cfDNA), Circulating tumour DNA (ctDNA).
Shares Read methylation and mutation on the same cell-free DNA fragment to tell what kind of cancer is left, DNA methylation profiling, Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares Cell-free DNA methylation tests, Cell-free DNA (cfDNA), DNA methylation profiling, Circulating tumour DNA (ctDNA).
Shares Read methylation and mutation on the same cell-free DNA fragment to tell what kind of cancer is left, Naming which clone or phenotype is left after treatment, DNA methylation profiling.
Shares Naming which clone or phenotype is left after treatment, Estrogen receptor (ERα), Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/